News
Local
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate News
Hot Property
eNewspaper
________________
Subscriptions
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
About Us
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Events
Advertising
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Jobs
CaregiverSD
Community papers
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Games, Puzzles, and Crossword
Crossword
Sudoku
Crossword
Sudoku
Obituaries
Death Notices
Place an obituary
Death Notices
Place an obituary
U-T En Español
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Privacy and Terms
Privacy
Terms
Advertising terms
Privacy
Terms
Advertising terms
Copyright © 2022, The San Diego Union-Tribune |
CA Notice of Collection
|
Do Not Sell My Personal Information
Sections
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate
Obituaries
eNewspaper
Newsletters
Show Search
Search Query
Submit Search
COVID-19
For subscribers
Phenomenal women
Latino life
Crossword
Sudoku
About Us
Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Diego Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Horizon Therapeutics plc
< Previous
1
2
3
4
5
6
Next >
Horizon Therapeutics plc Announces Data from the TEPEZZA® (teprotumumab-trbw) Phase 4 Clinical Trial in Patients with Chronic/Low CAS Thyroid Eye Disease (TED) to be Presented at the Upcoming Endocrine Society (ENDO) Annual Meeting
June 05, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
June 02, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Biomarker Analysis Publication Highlights Key Signals of Disability Worsening Associated With Neuromyelitis Optica Spectrum Disorder (NMOSD) Attacks, Illustrates Efficacy of UPLIZNA® (inebilizumab-cdon)
June 01, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Presentations at the 2023 EULAR European Congress of Rheumatology Highlight New Results from Phase 2 Trial Evaluating Dazodalibep in Sjögren’s Syndrome
May 31, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
New Analyses of the MIRROR Randomized Controlled Trial in Uncontrolled Gout Presented at the 2023 EULAR European Congress of Rheumatology
May 31, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc Announces Presentation of Data that Advances the Understanding of Rheumatic Diseases at the 2023 EULAR European Congress of Rheumatology
May 23, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc Responds to U.S. Federal Trade Commission (FTC) Action to Block Acquisition by Amgen
May 16, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
May 10, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc Ranks First in Overall Corporate Reputation by U.S. Patient Advocacy Groups
May 09, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc (“Horizon”) - Rule 2.12 Announcement
May 04, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc Reports First-Quarter 2023 Financial Results
May 03, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab for the Treatment of Lupus Nephritis
May 02, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc Ranks First in Patient Centricity and Integrity by Patient Advocacy Groups According to New PatientView Survey
May 02, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
May 01, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc Announces Initiation of Phase 3 Clinical Trial in Japan Evaluating TEPEZZA® (teprotumumab-trbw) in Adults with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED)
May 01, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc Announces UPLIZNA® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be Presented at the 2023 American Academy of Neurology (AAN) Annual Meeting
April 20, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc and Massachusetts Institute of Technology (MIT) Solve Announce the Launch of the Third Annual Horizon Prize to Inspire Sustainable Solutions for Research and Care in the Rare Disease Community
April 18, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics Announces Date of Irish Court Hearing to Sanction Scheme of Arrangement
April 17, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc Announces FDA Approval of an Update to the Indication Language for TEPEZZA® (teprotumumab-trbw) to Specify its Use in Thyroid Eye Disease (TED) Patients Regardless of Disease Activity or Duration
April 14, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc to Release First-Quarter 2023 Financial Results on May 3, 2023
April 14, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc Announces Positive Topline Data from TEPEZZA® (teprotumumab-trbw) Phase 4 Clinical Trial in Patients with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED)
April 10, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc Named to the 2023 Fortune 100 Best Companies to Work For List
April 04, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
March 16, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
New Analysis of MRI Findings Show UPLIZNA® (inebilizumab-cdon) Reduced the Formation of Asymptomatic Optic Nerve Lesions in People With Neuromyelitis Optica Spectrum Disorder (NMOSD)
March 14, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Real-World Experience Shows TEPEZZA® (teprotumumab-trbw) Was Effective in Treating People With Dysthyroid Optic Neuropathy (DON)
March 12, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc - Rule 2.12 Announcement
March 01, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc Reports Fourth-Quarter and Full-Year 2022 Financial Results
March 01, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc Opens Applications for #RAREis Global Advocate Grant Program
February 28, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc Announces Voting Results from Special Shareholder Meetings
February 24, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
New Data Suggest UPLIZNA® (inebilizumab-cdon) for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD) Did Not Increase the Risk of COVID-19 Infection or Reduce Antibody Levels From Childhood Vaccines
February 23, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.